We are live on ! Find out more
OMGA

Omega Therapeutics, Inc. Common Stock

Delisted

OMGA was delisted on the 24th of February, 2025.

58 hedge funds and large institutions have $109M invested in Omega Therapeutics, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

148% more call options, than puts

Call options by funds: $99K | Put options by funds: $40K

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

0% more funds holding

Funds holding: 5858 (0)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

0% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 6

62% less capital invested

Capital invested by funds: $286M → $109M (-$177M)

Holders
58
Holders Change
Holders Change %
0%
% of All Funds
0.92%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
6
Increased
22
Reduced
13
Closed
6
Calls
$99K
Puts
$40K
Net Calls
+$59K
Net Calls Change
+$1K

OMGA Hedge Fund Activity: Q3 2023 in Review

58 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Omega Therapeutics, Inc. Common Stock (OMGA) for Q3 2023, worth a combined $109M — down 62% from $286M a quarter earlier.

Fund positioning in OMGA was balanced in Q3 2023: 6 funds opened new positions, 6 closed out, 22 added to existing stakes and 13 trimmed.

The largest buyer was Millennium Management, adding an estimated $496K. The largest seller was Fidelity Investments, cutting an estimated $962K.

  • 58 institutional investors held Omega Therapeutics, Inc. Common Stock (OMGA) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $109M of Omega Therapeutics, Inc. Common Stock stock for Q3 2023, down 62% quarter-over-quarter.
  • 6 funds opened new Omega Therapeutics, Inc. Common Stock positions in Q3 2023 and 6 closed out, a net change of 0 holders.
  • The largest Omega Therapeutics, Inc. Common Stock buyer in Q3 2023 was Millennium Management, an estimated $496K added.
  • The largest Omega Therapeutics, Inc. Common Stock seller in Q3 2023 was Fidelity Investments, an estimated $962K sold.

Based on aggregated 13F filings for Q3 2023.